The Medical Letter on Drugs and Therapeutics
Trelegy Ellipta - A Three-Drug Inhaler for COPD
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved Trelegy Ellipta (GSK), a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, the long-acting antimuscarinic agent (LAMA) umeclidinium, and the long-acting beta2-agonist (LABA) vilanterol. It is available as a dry powder inhaler for once-daily maintenance treatment of COPD and to reduce COPD exacerbations in patients with a history of exacerbations. Trelegy Ellipta is the first three-drug inhaler for treatment of COPD to become available in the US.

MAINTENANCE TREATMENT OF COPD — For patients who have COPD symptoms or are at increased risk of exacerbations, maintenance inhalation treatment with an inhaled LABA or (preferably) LAMA can relieve symptoms, improve lung function, and reduce exacerbation frequency. Patients with COPD that is inadequately controlled with monotherapy should receive a LAMA and a LABA. An ICS plus a LABA appears to ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Trelegy Ellipta - A Three-Drug Inhaler for COPD
Article code: 1547c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian